Omega Therapeutics (OMGAQ) Stock Price, News & Analysis

Company Overview

Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $0.02 to $0.03
• 50-Day Range: $0.02 to $0.13
• 52-Week Range: $0.01 to $1.97
• Volume: 32,967 shs
• Average Volume: 800,577 shs
• Market Capitalization: $1.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.50
• Consensus Rating: Moderate Buy

Omega Therapeutics Stock Analysis - MarketRank™

Omega Therapeutics scored higher than 46% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Omega Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Omega Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Omega Therapeutics are expected to grow in the coming year, from ($1.25) to ($0.99) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Omega Therapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Omega Therapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Omega Therapeutics has a P/B Ratio of 0.02. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for OMGAQ.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Omega Therapeutics does not currently pay a dividend.

Dividend Growth

Omega Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for OMGAQ.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

5 people have searched for OMGAQ on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.

MarketBeat Follows

4 people have added Omega Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Omega Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 8.50% of the stock of Omega Therapeutics is held by insiders.

Percentage Held by Institutions

97.47% of the stock of Omega Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

OMGAQ Stock Analysis - Frequently Asked Questions

How have OMGAQ shares performed this year?

Omega Therapeutics' stock was trading at $0.7456 at the start of the year. Since then, OMGAQ shares have decreased by 97.5% and is now trading at $0.0185.

How were Omega Therapeutics' earnings last quarter?

Omega Therapeutics, Inc. (OTCMKTS:OMGAQ) announced its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.06. The company had revenue of $2.13 million for the quarter, compared to analyst estimates of $1.25 million.

How do I buy shares of Omega Therapeutics?

Shares of OMGAQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/06/2024
• Today: 7/24/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: N/A
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:OMGAQ
• Previous Symbol: NASDAQ:OMGA
• CIK: 1850838
• Web: www.omegatherapeutics.com
• Phone: 617-949-4360
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Omega Therapeutics: $8.50
• High Price Target: $12.00
• Low Price Target: $4.00
• Potential Upside/Downside: +34,313.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $3.09 million
• Price / Sales: 0.44
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.05 per share
• Price / Book: 0.02

Miscellaneous

• Outstanding Shares: 55,366,000
• Free Float: 50,660,000
• Market Cap: $1.37 million
• Optionable: Optionable
• Beta: 0.63